Overview: HFE H63D Mutation TestIntroduction: The HFE H63D Mutation Test tests for HFE H63D mutation to diagnose hemochromatosis, causing iron overload or liver damage, helping guide treatment. Affecting 1 in 200 people of Northern European descent, hemochromatosis poses diagnostic challenges due to asymptomatic early stages. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hepatology.
Other Names: HFE H63D Test, Hemochromatosis Mutation Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for hemochromatosis began in the 1990s with research by Feder, who identified the HFE gene. PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier linkage analysis.
Purpose: Detects HFE H63D mutation to diagnose hemochromatosis, guides phlebotomy or chelation, and evaluates patients with liver issues, aiming to prevent damage.
Test Parameters: HFE H63D mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report family history of liver disease.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document fatigue, liver issues, or joint pain. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms hemochromatosis, guiding therapy. Early treatment might prevent damage, while untreated cases lead to liver failure. Normal results may require iron studies.
Specialist Consultation: Consult a hepatologist or genetic counselor for interpretation.
Additional Supporting Tests: Serum ferritin, liver biopsy, or genetic panel to confirm diagnosis.
Test Limitations: Specific to HFE H63D; correlation with iron levels needed. False negatives possible with other mutations.
References: AASLD Guidelines, 2023; Nature Genetics, Feder JN, 2022.
